Literature DB >> 8044933

Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only.

E Brogi1, T Wu, A Namiki, J M Isner.   

Abstract

BACKGROUND: Hypoxia and indirect angiogenic factors may stimulate angiogenesis via induction of endothelial cell mitogen(s). To evaluate this hypothesis, we investigated whether low oxygen tension or cytokines known to promote neovascularization in vivo could modulate the expression of either vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) in human vascular smooth muscle cells (SMCs). METHODS AND
RESULTS: SMCs were treated with platelet-derived growth factor BB (PDGF-BB) or transforming growth factor-beta 1 (TGF-beta 1) or exposed to low oxygen tension in serum-free medium. Northern analysis detected low basal levels of VEGF and bFGF mRNA in extracts of unstimulated SMCs. However, both VEGF and bFGF transcripts increased after administration of PDGF-BB (10 or 20 ng/mL) or TGF-beta 1 (0.1 to 10 ng/mL). Hypoxia was a potent stimulus for VEGF gene expression but had no apparent effect on bFGF steady-state mRNA levels.
CONCLUSIONS: These results indicate that certain indirect angiogenic cytokines, such as PDGF-BB or TGF-beta 1, may act via induction of bFGF and VEGF gene expression in cells resident near endothelial cells in vivo. Hypoxia constitutes a potent stimulus for VEGF gene expresion but does not regulate bFGF under the same experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044933     DOI: 10.1161/01.cir.90.2.649

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  86 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

Review 2.  Cellular adaptive responses to low oxygen tension: apoptosis and resistance.

Authors:  J K Yun; T S McCormick; R Judware; E G Lapetina
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

3.  Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries.

Authors:  T Couffinhal; M Kearney; B Witzenbichler; D Chen; T Murohara; D W Losordo; J Symes; J M Isner
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 4.  Molecular imaging of cardiovascular gene products.

Authors:  Joseph C Wu; Jeffrey R Tseng; Sanjiv S Gambhir
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

5.  Microvascular endothelial cells sustain preadipocyte viability under hypoxic conditions.

Authors:  Cynthia A Frye; Xuemei Wu; Charles W Patrick
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 May-Jun       Impact factor: 2.416

Review 6.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

7.  Stretch-induced VEGF expression in the heart.

Authors:  J Li; T Hampton; J P Morgan; M Simons
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 8.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

9.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia.

Authors:  B Witzenbichler; T Asahara; T Murohara; M Silver; I Spyridopoulos; M Magner; N Principe; M Kearney; J S Hu; J M Isner
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.

Authors:  L F Brown; K Tognazzi; H F Dvorak; T J Harrist
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.